glp-1 suicide Reassuring' findings suggest receptor agonists do not increase risk FDA Asks Novo, Lilly To
Description
However, these are generally not a concern with typical consumption levels
The Phase 1 trial plans to enroll 32 healthy participants, divided into 4 cohorts, with each cohort consisting of 8 participants receiving IBI3032 or placebo in a 6:2
Aghajani E, Nergaard BJ, Leifson BG, et al
Jin Y, Dong H, Xia L, et al
C Pharmacol
This action tells your body to: These combined effects help lower blood glucose levels and support weight loss, which is why GLP-1 receptor agonists are used to treat type 2 diabetes and obesity
